文献速递淋巴瘤

PRMT5抑制使B细胞淋巴瘤对铁死亡敏感

PRMT5 inhibition sensitizes B-cell lymphoma cells to ferroptosis.
PubMed 文献 · Leukemia · 2026-04-17

本研究在DLBCL和MCL细胞中发现PRMT5通过AKT-MYC-ATF5轴上调SLC7A11抑制铁死亡,ATF5还促进ATF4表达形成异二聚体强化该网络。PRMT5抑制剂GSK3326595与DMF联用在PDX模型中协同增强抗肿瘤活性,提示靶向PRMT5可增强铁死亡疗法的潜力。

要点

  • PRMT5通过AKT-MYC-ATF5轴上调SLC7A11抑制B细胞淋巴瘤铁死亡。
  • ATF5促进ATF4表达并形成异二聚体,进一步强化铁死亡抵抗网络。
  • GSK3326595联合DMF在PDX模型中协同增强抗肿瘤活性。

核心结论

  • PRMT5通过AKT-MYC-ATF5-SLC7A11轴驱动B细胞淋巴瘤铁死亡抵抗,抑制PRMT5可增强铁死亡诱导剂的抗肿瘤活性。

研究设计与样本

  • 研究在DLBCL和MCL细胞中探讨PRMT5对铁死亡的调控机制,并在PDX模型中验证联合治疗效果。

主要发现

  • PRMT5通过AKT-MYC-ATF5信号轴上调SLC7A11,促进胱氨酸摄入和GSH合成,从而抑制铁死亡。
  • ATF5由MYC调控且在这些淋巴瘤中过表达,诱导SLC7A11表达并促进ATF4表达,两者形成异二聚体强化调控网络。
  • PRMT5抑制剂使淋巴瘤细胞对DMF等铁死亡诱导剂敏感,GSK3326595与DMF联用在PDX模型中协同增强抗肿瘤活性。

临床怎么用

  • 靶向PRMT5可能作为增强铁死亡基础疗法的手段,用于复发或难治性B细胞淋巴瘤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Protein arginine methyltransferase 5 (PRMT5) is overexpressed in B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). While PRMT5 is known to regulate multiple oncogenic pathways, including PI3K-AKT signaling, its role in lipid metabolism and ferroptosis, a regulated, iron-dependent cell death driven by lipid peroxidation, remains poorly understood. Here, we identify a novel role for PRMT5 in suppressing ferroptosis in DLBCL and MCL cells through upregulation of SLC7A11, which imports cystine for glutathione (GSH) biosynthesis. This effect is mediated by the AKT-MYC-ATF5 signaling axis. ATF5, a MYC-regulated transcription factor overexpressed in these lymphomas, induces SLC7A11 expression. In addition, ATF5 promotes the expression of ATF4, another key regulator of the ferroptotic response, which forms heterodimers with ATF5 to further reinforce this regulatory network. PRMT5 inhibition sensitizes lymphoma cells to ferroptosis inducers such as dimethyl fumarate (DMF), an electrophile that irreversibly depletes GSH via succination. Notably, combined treatment with the PRMT5 inhibitor GSK3326595 and DMF synergistically enhances anti-tumor activity in a patient-derived xenograft (PDX) model. These findings reveal a previously unrecognized PRMT5-ATF5-SLC7A11 axis that drives ferroptosis resistance in B-cell lymphomas and provide a strong rationale for targeting PRMT5 to potentiate ferroptosis-based therapies in relapsed or refractory disease.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Liu Y, Chen R, Gao X, et al. PRMT5 inhibition sensitizes B-cell lymphoma cells to ferroptosis. Leukemia. 2026. PMID: 41998301. doi:10.1038/s41375-026-02932-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。